Literature DB >> 15967087

Medullary thyroid carcinoma: management of lymph node metastases.

Frank Jay Quayle1, Jeffrey F Moley.   

Abstract

Medullary thyroid carcinoma (MTC) is a neuroendocrine malignancy of the thyroid C cells. Spread of MTC commonly occurs to cervical and mediastinal lymph nodes. MTC cells do not concentrate radioactive iodine, and are not sensitive to hormonal manipulation. Because of these features, the treatment of metastatic or recurrent MTC is different from the treatment of differentiated thyroid cancer. Surgery is the only effective therapy at present that can result in cure, or reduction in tumor burden, or effective palliation. Systematic surgical removal of at-risk or involved lymph node basins should be done in patients with palpable primary tumors and recurrence. A "berry-picking" approach is discouraged. Although data are limited, standard chemotherapy and radiation therapy have not been effective in the treatment of MTC. Newer targeted drug therapies are being examined in therapeutic clinical trials.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15967087     DOI: 10.1007/s11864-005-0038-6

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  18 in total

1.  Lymph node dissection and medullary thyroid carcinoma.

Authors:  H Dralle
Journal:  Br J Surg       Date:  2002-09       Impact factor: 6.939

2.  Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma.

Authors:  J A van Heerden; C S Grant; H Gharib; I D Hay; D M Ilstrup
Journal:  Ann Surg       Date:  1990-10       Impact factor: 12.969

Review 3.  ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes.

Authors:  José G Guillem; William C Wood; Jeffrey F Moley; Andrew Berchuck; Beth Y Karlan; David G Mutch; Robert F Gagel; Jeffrey Weitzel; Monica Morrow; Barbara L Weber; Francis Giardiello; Miguel A Rodriguez-Bigas; James Church; Stephen Gruber; Kenneth Offit
Journal:  Ann Surg Oncol       Date:  2006-10       Impact factor: 5.344

4.  Clinical characteristics in sporadic and familial medullary thyroid carcinoma. A nationwide study of 249 patients in Sweden from 1959 through 1981.

Authors:  U Bergholm; H O Adami; R Bergström; H Johansson; G Lundell; M Telenius-Berg; G Akerström
Journal:  Cancer       Date:  1989-03-15       Impact factor: 6.860

5.  Evaluation of fluorodeoxyglucose-positron emission tomographic scanning and its association with glucose transporter expression in medullary thyroid carcinoma and pheochromocytoma: a clinical and molecular study.

Authors:  T J Musholt; P B Musholt; F Dehdashti; J F Moley
Journal:  Surgery       Date:  1997-12       Impact factor: 3.982

6.  Early malignant progression of hereditary medullary thyroid cancer.

Authors:  Andreas Machens; Patricia Niccoli-Sire; Josef Hoegel; Karin Frank-Raue; Theo J van Vroonhoven; Hans-Dietrich Roeher; Robert A Wahl; Peter Lamesch; Friedhelm Raue; Bernard Conte-Devolx; Henning Dralle
Journal:  N Engl J Med       Date:  2003-10-16       Impact factor: 91.245

7.  Potential absence of prognostic implications of severe preoperative hypercalcitoninemia in medullary thyroid carcinoma.

Authors:  Farhad Zangeneh; Hossein Gharib; John R Goellner; Pai Chih Kao
Journal:  Endocr Pract       Date:  2003 Jul-Aug       Impact factor: 3.443

8.  Surgical management of patients with persistent or recurrent medullary thyroid cancer.

Authors:  J F Moley; M K Debenedetti; W G Dilley; L E Tisell; S A Wells
Journal:  J Intern Med       Date:  1998-06       Impact factor: 8.989

9.  Progression of postoperative residual medullary thyroid carcinoma as monitored by plasma calcitonin levels.

Authors:  L E Tisell; W G Dilley; S A Wells
Journal:  Surgery       Date:  1996-01       Impact factor: 3.982

10.  Laparoscopic detection of hepatic metastases in patients with residual or recurrent medullary thyroid cancer.

Authors:  W S Tung; T M Vesely; J F Moley
Journal:  Surgery       Date:  1995-12       Impact factor: 3.982

View more
  6 in total

1.  SPECT/CT and PET/CT molecular imaging in medullary thyroid carcinoma. Are we running in the right direction?

Authors:  Anna Margherita Maffione; Francesco Giammarile; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-22       Impact factor: 9.236

Review 2.  Evidence-based approach to the management of sporadic medullary thyroid carcinoma.

Authors:  Jeffrey F Moley; Elizabeth A Fialkowski
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

3.  New agent to treat advanced or metastasized thyroid cancer, its efficacy, safety, and mechanism.

Authors:  Huan-Gao Zhu; Jun-Yu Zhao; Rui Zhang; Lin Liao; Jian-Jun Dong
Journal:  Thorac Cancer       Date:  2015-02-17       Impact factor: 3.500

Review 4.  Vandetanib: in medullary thyroid cancer.

Authors:  James E Frampton
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

Review 5.  Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension.

Authors:  Rikke Vilsbøll Milling; Daniela Grimm; Marcus Krüger; Jirka Grosse; Sascha Kopp; Johann Bauer; Manfred Infanger; Markus Wehland
Journal:  Int J Mol Sci       Date:  2018-10-20       Impact factor: 5.923

6.  MicroRNA-375/SEC23A as biomarkers of the in vitro efficacy of vandetanib.

Authors:  Sandra Lassalle; Joséphine Zangari; Alexandra Popa; Marius Ilie; Véronique Hofman; Elodie Long; Martine Patey; Frédérique Tissier; Geneviève Belléannée; Hélène Trouette; Bogdan Catargi; Isabelle Peyrottes; Jean-Louis Sadoul; Olivier Bordone; Christelle Bonnetaud; Catherine Butori; Alexandre Bozec; Nicolas Guevara; José Santini; Imène Sarah Hénaoui; Géraldine Lemaire; Olivier Blanck; Philippe Vielh; Pascal Barbry; Bernard Mari; Patrick Brest; Paul Hofman
Journal:  Oncotarget       Date:  2016-05-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.